Rhythm Pharmaceuticals, Inc.
RM-718
acquired hypothalamic obesity
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for RM-718 (acquired hypothalamic obesity) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Complete enrollment in the Phase 1, Part C trial evaluating the weekly, MC4R agonist RM-718 in patients with acquired HO in the first quarter of 2026.”